{"name":"Pargyline","slug":"pargyline","kind":"substance","abbreviations":[],"systematic":null,"aliases":["N-Methyl-N-propargylbenzylamine","Pargylamine","Eudatin","Paragyline","Supirdyl","N-Methyl-N-2-propynylbenzylamine","Pargilina","Pargylinum","Benzenemethanamine, N-methyl-N-2-propynyl-","benzyl(methyl)(prop-2-yn-1-yl)amine"],"brands":[],"scraped":true,"has_structure":true,"cid":4688,"classes":[{"name":"monoamine oxidase inhibitor","href":"/class/monoamine_oxidase_inhibitor"}],"families":[{"name":"benzylamine","href":"/substituted/benzylamine"}],"physical":[{"label":"Molecular mass","value":"159.23 g/mol","copyable":false},{"label":"Solubility","value":"9.98e-02 g/L","copyable":false},{"label":"Predicted LogP","value":"2.1","copyable":false}],"identifiers":[{"label":"Molecular formula","value":"C<sub>11</sub>H<sub>13</sub>N","copyable":true},{"label":"IUPAC name","value":"N-benzyl-N-methylprop-2-yn-1-amine","copyable":true},{"label":"SMILES","value":"CN(CC#C)CC1=CC=CC=C1","copyable":true},{"label":"InChI","value":"InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3","copyable":true},{"label":"InChIKey","value":"DPWPWRLQFGFJFI-UHFFFAOYSA-N","copyable":true},{"label":"CAS number","value":"555-57-7","copyable":true},{"label":"UNII","value":"9MV14S8G3E","copyable":true},{"label":"PubChem CID","value":"4688","copyable":true}],"pharmacokinetics":[{"label":"Routes of administration","value":"Oral<a href=\"#cite_note-3\"><sup>[3]</sup></a>","copyable":false}],"toxicity":[],"dosing":null,"salts":[{"title":"Pargyline hydrochloride","name":"hydrochloride","slug":"pargyline_hydrochloride","drawn":true}],"esters":[],"chirality":"achiral","stereo_type":null,"optical_activity":null,"stereoisomers":[],"lipinski":{"passes":true,"violations":0},"reagents":[],"atc":[{"code":"C","description":"Cardiovascular system"},{"code":"C02","description":"Antihypertensives"},{"code":"C02K","description":"Other antihypertensives"},{"code":"C02KC","description":"Mao inhibitors"},{"code":"C02KC01","description":"Pargyline"}],"mesh":[{"name":"Antihypertensive Agents","id":"M0001456"},{"name":"Monoamine Oxidase Inhibitors","id":"M0014029"}],"actives":[],"prodrugs":[],"codrug":false,"interactions":[{"target":"MAOB","mechanisms":["shared target"],"partners":3,"contraindicated":3}],"mechanism":"MAOIs act by inhibiting the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. There are two isoforms of monoamine oxidase, MAO-A and MAO-B. MAO-A preferentially deaminates serotonin, melatonin, epinephrine and norepinephrine. MAO-B preferentially deaminates phenylethylamine and trace amines. Pargyline functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Catecholamines cause general physiological changes that prepare the body for physical activity (fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system.","side_effects":null,"effects":null,"usernotes":[],"erowid":[],"reddit":[],"legal":[],"members":[],"part_of":[],"links":[{"source":"Wikipedia","url":"https://en.wikipedia.org/wiki/Pargyline"},{"source":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/4688"},{"source":"Wikidata","url":"https://www.wikidata.org/wiki/Q781329"},{"source":"DrugBank","url":"https://go.drugbank.com/drugs/DB01626"},{"source":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL673"},{"source":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI%3A7930"},{"source":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=555-57-7"},{"source":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0015563"},{"source":"KEGG","url":"https://www.kegg.jp/entry/C07414"},{"source":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID3023423"},{"source":"Effect Index","url":"https://www.effectindex.com/search?q=Pargyline"},{"source":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/9MV14S8G3E"}],"references":["National Center for Biotechnology Information. PubChem Compound Summary for CID 4688, Pargyline. Accessed November 20, 2026. <a href=https://pubchem.ncbi.nlm.nih.gov/compound/4688>https://pubchem.ncbi.nlm.nih.gov/compound/4688</a>","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Pargyline. UNII: 9MV14S8G3E. Global Substance Registration System. Accessed November 20, 2026. <a href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/9MV14S8G3E>https://gsrs.ncats.nih.gov/ginas/app/beta/substances/9MV14S8G3E</a>","Hayes AH, Schneck DW. Antihypertensive pharmacotherapy. Postgraduate Medicine. May 1976; 59(5):155–162. PMID 57611. <a href='https://doi.org/10.1080/00325481.1976.11714363'>https://doi.org/10.1080/00325481.1976.11714363</a>"],"sources":[{"source":"dosing","status":"missing","fetched_at":"2026-11-20 10:00:57","note":"no dosing statistics"},{"source":"drugspro","status":"missing","fetched_at":"2026-11-20 10:00:53","note":"no DrugsPRO reagent data"},{"source":"erowid","status":"missing","fetched_at":"2026-11-20 10:00:53","note":"no Erowid substance of that name"},{"source":"gsrs","status":"ok","fetched_at":"2026-11-20 10:00:54","note":null},{"source":"hmdb","status":"missing","fetched_at":"2026-11-20 10:00:53","note":"hmdb.ca refused automated access to HMDB0015563"},{"source":"kegg","status":"ok","fetched_at":"2026-11-20 10:00:55","note":null},{"source":"pubchem","status":"ok","fetched_at":"2026-11-20 10:00:53","note":null},{"source":"reddit","status":"missing","fetched_at":"2026-11-20 10:00:53","note":"no r/tripreports posts mention it"},{"source":"sider","status":"missing","fetched_at":"2026-11-20 10:00:53","note":"not in SIDER"},{"source":"structure","status":"ok","fetched_at":"2026-11-20 10:00:53","note":null},{"source":"wikipedia","status":"ok","fetched_at":"2026-11-20 10:00:53","note":null}],"description":"Pargyline is a monoamine oxidase inhibitor substance."}